MAMDC2

Summary

MAMDC2 (MAM domain containing 2, HGNC:23673) is a protein-coding gene on chromosome 9q21.12, encoding MAM domain-containing protein 2 (Q7Z304).

Predicted to enable glycosaminoglycan binding activity. Located in endoplasmic reticulum.

Source: NCBI Gene 256691 — RefSeq curated summary.

At a glance

• Gene–disease (curated): muscular dystrophy (Moderate, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 109 total
• MANE Select transcript: NM_153267

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23673
Approved symbol	MAMDC2
Name	MAM domain containing 2
Location	9q21.12
Locus type	gene with protein product
Status	Approved
Aliases	MGC21981
Ensembl gene	ENSG00000165072
Ensembl biotype	protein_coding
OMIM	612879
Entrez	256691

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000377182, ENST00000460688, ENST00000864379, ENST00000864380, ENST00000864381, ENST00000911415

RefSeq mRNA: 2 — MANE Select: NM_153267 NM_001347990, NM_153267

CCDS: CCDS6631

Canonical transcript exons

ENST00000377182 — 14 exons

Exon	Start	End
ENSE00000917491	70170479	70170631
ENSE00000982756	70218337	70218596
ENSE00000982757	70225750	70225834
ENSE00001128960	70168702	70168795
ENSE00001208303	70143554	70143819
ENSE00001356398	70140145	70140288
ENSE00001356402	70131519	70131612
ENSE00001356406	70126159	70126415
ENSE00001356409	70112995	70113132
ENSE00001356412	70109720	70109804
ENSE00001356418	70108211	70108482
ENSE00001356423	70044584	70044697
ENSE00001473031	70225968	70226972
ENSE00001473053	70043848	70044231

Expression profiles

Bgee: expression breadth ubiquitous, 221 present calls, max score 98.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.1959 / max 1464.8753, expressed in 977 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96857	6.4199	603
96858	3.0574	544
96856	1.9417	435
96859	1.5844	527
96860	0.7318	341
96862	0.7160	335
96851	0.7115	158
96854	0.3249	176
96861	0.1756	105
96855	0.1302	59

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of stomach	UBERON:0001199	98.54	gold quality
synovial joint	UBERON:0002217	98.46	gold quality
lower lobe of lung	UBERON:0008949	97.32	gold quality
right lung	UBERON:0002167	97.07	gold quality
cauda epididymis	UBERON:0004360	96.13	gold quality
layer of synovial tissue	UBERON:0007616	95.95	gold quality
decidua	UBERON:0002450	95.84	gold quality
left uterine tube	UBERON:0001303	95.77	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.64	gold quality
body of uterus	UBERON:0009853	95.13	gold quality
upper arm skin	UBERON:0004263	94.96	gold quality
calcaneal tendon	UBERON:0003701	94.72	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.16	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.03	gold quality
lower esophagus	UBERON:0013473	93.95	gold quality
urethra	UBERON:0000057	93.60	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.56	gold quality
oral cavity	UBERON:0000167	93.48	gold quality
skin of hip	UBERON:0001554	93.24	gold quality
left ovary	UBERON:0002119	92.68	gold quality
right ovary	UBERON:0002118	92.57	gold quality
pharyngeal mucosa	UBERON:0000355	92.15	gold quality
corpus epididymis	UBERON:0004359	91.78	gold quality
tendon of biceps brachii	UBERON:0008188	91.72	gold quality
lung	UBERON:0002048	91.69	gold quality
myometrium	UBERON:0001296	91.54	gold quality
endocervix	UBERON:0000458	91.45	gold quality
tendon	UBERON:0000043	91.16	gold quality
upper lobe of lung	UBERON:0008948	91.02	gold quality
mammary duct	UBERON:0001765	90.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	30.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

91 targeting MAMDC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-300	99.92	71.76	2856

Literature-anchored findings (GeneRIF, showing 2)

• MAM domain containing 2 is a potential breast cancer biomarker that exhibits tumour-suppressive activity. (PMID:32707597)
• Ablation of the carboxy-terminal end of MAMDC2 causes a distinct muscular dystrophy. (PMID:37503746)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mamdc2a	ENSDARG00000098345
mus_musculus	Mamdc2	ENSMUSG00000033207
rattus_norvegicus	Mamdc2	ENSRNOG00000024620

Paralogs (4): MDGA1 (ENSG00000112139), MDGA2 (ENSG00000139915), MAMDC4 (ENSG00000177943), MALRD1 (ENSG00000204740)

Protein

Protein identifiers

MAM domain-containing protein 2 — Q7Z304 (reviewed: Q7Z304)

Alternative names: MAM domain-containing proteoglycan

All UniProt accessions (1): Q7Z304

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. O-glycosylated.

Isoforms (2)

UniProt ID	Names	Canonical?
Q7Z304-1	1	yes
Q7Z304-2	2

RefSeq proteins (2): NP_001334919, NP_694999* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000998	MAM_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR051560	MAM_domain-containing	Family

Pfam: PF00629

UniProt features (14 total): domain 4, glycosylation site 3, sequence variant 2, region of interest 2, signal peptide 1, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z304-F1	84.97	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 524, 134, 329

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN, ATGCAGT_MIR217, AP1_Q4_01, BACH2_01, TGANTCA_AP1_C, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, SABATES_COLORECTAL_ADENOMA_DN, HAND1E47_01, VECCHI_GASTRIC_CANCER_EARLY_DN, RIGGI_EWING_SARCOMA_PROGENITOR_UP, HOXA4_Q2, ZHENG_BOUND_BY_FOXP3, chr9q21, MALONEY_RESPONSE_TO_17AAG_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), membrane (GO:0016020), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1094 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAMDC2	PTPRM	P28827	487
MAMDC2	FAM163A	Q96GL9	462
MAMDC2	NCAPD3	P42695	410
MAMDC2	TSN	Q15631	405
MAMDC2	RAB21	Q9UL25	395
MAMDC2	FRAS1	Q86XX4	372
MAMDC2	CHRDL1	Q9BU40	358
MAMDC2	ABI3BP	Q7Z7G0	357
MAMDC2	ECRG4	Q9H1Z8	348
MAMDC2	TAFA1	Q7Z5A9	343
MAMDC2	TEX29	Q8N6K0	342
MAMDC2	HPSE2	Q8WWQ2	338
MAMDC2	KERA	O60938	334
MAMDC2	NSUN3	Q9H649	331
MAMDC2	PRC1	O43663	325

IntAct

7 interactions, top by confidence:

A	B	Type	Score
EFHC1	MAMDC2	psi-mi:“MI:0915”(physical association)	0.560
MAMDC2	FLNA	psi-mi:“MI:0915”(physical association)	0.400
MAMDC2	CDAN1	psi-mi:“MI:0914”(association)	0.350
Smad6	DDX1	psi-mi:“MI:0914”(association)	0.350
EFHC1	MAMDC2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (13): EIF4G1 (Affinity Capture-MS), RNASEH2A (Affinity Capture-MS), TK1 (Affinity Capture-MS), TAB1 (Affinity Capture-MS), CDAN1 (Affinity Capture-MS), TK1 (Affinity Capture-MS), EIF4G1 (Affinity Capture-MS), MAMDC2 (Affinity Capture-RNA), MAMDC2 (Two-hybrid), MAMDC2 (Proximity Label-MS), DNAJB8 (Affinity Capture-MS), CDAN1 (Affinity Capture-MS), MAMDC2 (Affinity Capture-MS)

ESM2 similar proteins: A0EQL2, A2AJ76, A2AJA7, A6H8M9, A8T650, A8T682, A8T688, A8T6A6, D3ZLH5, F1QVU0, O08628, O75173, O88839, P04278, P08514, P08689, P0DV84, P15196, P20701, P29376, P32970, P38570, P60882, P80012, P97497, P97793, Q13444, Q15113, Q5RFQ8, Q5TM20, Q61398, Q63191, Q6UXC1, Q7Z304, Q7Z442, Q7Z7M0, Q8BNJ2, Q8CG85, Q8K1S7, Q8NBP7

Diamond homologs: A0A6I8TCE0, A2A8L5, A2AJX4, A7MBJ4, B0X4T2, B3EWZ5, B3EWZ6, B3EX02, B7T7N1, F1NWE3, O00533, O15197, P0C0K6, P10586, P13944, P14781, P23468, P29317, P35331, P35832, P60755, P60756, P70232, P85171, P97686, P98073, Q07497, Q0PMG2, Q0WYX8, Q13332, Q1KL86, Q28902, Q3UH53, Q58EX2, Q5VYJ5, Q60ZN5, Q61330, Q64487, Q64604, Q6V4S5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

109 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	4
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

3134 predictions. Top by Δscore:

Variant	Effect	Δscore
9:70044693:GGAAG:G	donor_gain	1.0000
9:70044694:GAAGG:G	donor_gain	1.0000
9:70044695:A:T	donor_gain	1.0000
9:70044695:AAGG:A	donor_loss	1.0000
9:70044697:GGTA:G	donor_loss	1.0000
9:70044699:T:A	donor_loss	1.0000
9:70108207:CCA:C	acceptor_loss	1.0000
9:70108208:CA:C	acceptor_loss	1.0000
9:70108209:A:AC	acceptor_loss	1.0000
9:70108209:A:AG	acceptor_gain	1.0000
9:70108209:AG:A	acceptor_gain	1.0000
9:70108210:G:GA	acceptor_gain	1.0000
9:70108210:GG:G	acceptor_gain	1.0000
9:70108210:GGC:G	acceptor_gain	1.0000
9:70108210:GGCC:G	acceptor_gain	1.0000
9:70108210:GGCCA:G	acceptor_gain	1.0000
9:70108483:G:GG	donor_gain	1.0000
9:70108483:GTA:G	donor_loss	1.0000
9:70109710:T:G	acceptor_gain	1.0000
9:70109715:TGCA:T	acceptor_loss	1.0000
9:70109716:GCA:G	acceptor_loss	1.0000
9:70109717:CA:C	acceptor_loss	1.0000
9:70109718:A:AG	acceptor_gain	1.0000
9:70109719:G:GG	acceptor_gain	1.0000
9:70109801:ATTGG:A	donor_loss	1.0000
9:70109805:G:C	donor_loss	1.0000
9:70109805:G:GG	donor_gain	1.0000
9:70109806:T:G	donor_loss	1.0000
9:70112991:CCA:C	acceptor_loss	1.0000
9:70112992:CAG:C	acceptor_loss	1.0000

AlphaMissense

4511 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:70113057:T:A	W190R	0.999
9:70113057:T:C	W190R	0.999
9:70126216:T:C	L234P	0.999
9:70113059:G:C	W190C	0.998
9:70113059:G:T	W190C	0.998
9:70140228:T:A	W360R	0.998
9:70140228:T:C	W360R	0.998
9:70112997:T:C	C170R	0.997
9:70126373:G:C	W286C	0.997
9:70126373:G:T	W286C	0.997
9:70131568:T:C	L317P	0.997
9:70140230:G:C	W360C	0.997
9:70140230:G:T	W360C	0.997
9:70170562:T:A	W528R	0.997
9:70170562:T:C	W528R	0.997
9:70113004:T:G	F172C	0.996
9:70143704:T:A	V430D	0.996
9:70168714:A:C	S473R	0.996
9:70168716:C:A	S473R	0.996
9:70168716:C:G	S473R	0.996
9:70170564:G:C	W528C	0.996
9:70170564:G:T	W528C	0.996
9:70108437:G:C	W125C	0.995
9:70108437:G:T	W125C	0.995
9:70112997:T:A	C170S	0.995
9:70112998:G:C	C170S	0.995
9:70112999:T:G	C170W	0.995
9:70126371:T:A	W286R	0.995
9:70126371:T:C	W286R	0.995
9:70143777:G:C	W454C	0.995

dbSNP variants (sampled 300 via entrez): RS1000016584 (9:70214106 T>A,C), RS1000016684 (9:70208906 T>C), RS1000040860 (9:70071363 T>A,C), RS1000045943 (9:70161912 A>C), RS1000053046 (9:70065150 A>G), RS1000060172 (9:70068149 T>A,C), RS1000061840 (9:70079175 C>A), RS1000099758 (9:70121550 C>G,T), RS1000157085 (9:70169085 A>G), RS1000198477 (9:70174367 G>A), RS1000228706 (9:70154398 A>T), RS1000253440 (9:70200058 A>G), RS1000275489 (9:70071170 C>CA), RS1000313405 (9:70220465 T>C), RS1000315347 (9:70062818 C>A,T)

Disease associations

OMIM: gene MIM:612879 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
muscular dystrophy	Moderate	Autosomal dominant

Mondo (2): prostate cancer (MONDO:0008315), muscular dystrophy (MONDO:0020121)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005580_253	Intraocular pressure	2.000000e-10
GCST005580_71	Intraocular pressure	1.000000e-11
GCST011390_4	Corneal resistance factor	2.000000e-55

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004695	intraocular pressure measurement
EFO:0010067	corneal resistance factor

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009136	Muscular Dystrophies	C05.651.534.500; C10.668.491.175.500; C16.320.577
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	5
bisphenol A	affects cotreatment, decreases methylation, decreases expression	3
trichostatin A	affects cotreatment, decreases expression	3
Air Pollutants	decreases expression, increases abundance	3
Particulate Matter	decreases expression, increases abundance	3
sodium arsenite	decreases expression	2
entinostat	decreases expression, affects cotreatment	2
monomethylarsonous acid	decreases expression, increases expression	2
Benzo(a)pyrene	decreases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
hydroxyhydroquinone	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
sulforaphane	decreases expression	1
triadimefon	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
dorsomorphin	increases expression, affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
incobotulinumtoxinA	affects expression	1
bisphenol AF	increases expression	1
Dasatinib	increases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Vorinostat	increases expression	1

Clinical trials (associated diseases)

430 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01882400	PHASE4	COMPLETED	Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer